Modeling the cellular response of lung cancer to radiation therapy for a broad range of fractionation schedules Journal Article
| Authors: | Jeong, J.; Oh, J. H.; Sonke, J. J.; Belderbos, J.; Bradley, J. D.; Fontanella, A. N.; Rao, S. S.; Deasy, J. O. |
| Article Title: | Modeling the cellular response of lung cancer to radiation therapy for a broad range of fractionation schedules |
| Abstract: | Purpose: To demonstrate that a mathematical model can be used to quantitatively understand tumor cellular dynamics during a course of radiotherapy and to predict the likelihood of local control as a function of dose and treatment fractions. Experimental Design: We model outcomes for early-stage, localized non–small cell lung cancer (NSCLC), by fitting a mechanistic, cellular dynamics-based tumor control probability that assumes a constant local supply of oxygen and glucose. In addition to standard radiobiological effects such as repair of sub-lethal damage and the impact of hypoxia, we also accounted for proliferation as well as radiosensitivity variability within the cell cycle. We applied the model to 36 published and two unpublished early-stage patient cohorts, totaling 2,701 patients. Results: Precise likelihood best-fit values were derived for the radiobiological parameters: a [0.305 Gy1; 95% confidence interval (CI), 0.120–0.365], the a/b ratio (2.80 Gy; 95% CI, 0.40–4.40), and the oxygen enhancement ratio (OER) value for intermediately hypoxic cells receiving glucose but not oxygen (1.70; 95% CI, 1.55–2.25). All fractionation groups are well fitted by a single dose–response curve with a high x2 P value, indicating consistency with the fitted model. The analysis was further validated with an additional 23 patient cohorts (n ¼ 1,628). The model indicates that hypofractionation regimens overcome hypoxia (and cell-cycle radiosensitivity variations) by the sheer impact of high doses per fraction, whereas lower dose-per-fraction regimens allow for reoxygenation and corresponding sensitization, but lose effectiveness for prolonged treatments due to proliferation. Conclusions: This proposed mechanistic tumor-response model can accurately predict overtreatment or undertreatment for various treatment regimens. ©2017 AACR. |
| Journal Title: | Clinical Cancer Research |
| Volume: | 23 |
| Issue: | 18 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2017-09-15 |
| Start Page: | 5469 |
| End Page: | 5479 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-16-3277 |
| PROVIDER: | scopus |
| PMCID: | PMC5600831 |
| PUBMED: | 28539466 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 October 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
187Oh -
524Deasy -
37Jeong -
14Fontanella
Related MSK Work